Dazhi Liu, Pharm.D., BCOP

Dazhi Liu is an oncology clinical pharmacy specialist and clinical trial investigator at Memorial Sloan Kettering Cancer Center. With extensive expertise in oncology pharmacotherapy, Liu has made significant contributions to the field through direct patient care, research and education.

Liu’s widely recognized research focuses on cancer diagnosis and treatment, therapeutic targets and translational research. She has presented her findings at major scientific conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting and the World Conference on Lung Cancer (WCLC).

Liu earned her doctorate in pharmacy and master’s degree in anatomy and cell biology and has demonstrated her commitment to advancing oncology through numerous publications in high-impact, peer-reviewed journals. Notable publications include studies on the safety and efficacy of pyrotinib in patients with non-small cell lung cancers (NSCLC), characterizing diverse targetable alterations in ERBB2 and ERBB3 in solid tumors, the use of ado-trastuzumab emtansine (T-DM1) in patients with ERBB2 alterations, and managing side effects from NTRK, RET, PI3K, and ERK inhibitors.

In addition to her research, Liu has been recognized for her teaching contributions, including her roles in courses such as Principles of Pharmacotherapy in Clinical and Translational Cancer Research at the MSKCC CTCR MD Master’s Program and the Cancer Engineering PhD Program.